About this trial
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.
Eligibility criteria
Qualifiers
Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements.
Planned to receive cisplatin-based NAC followed by radical cystectomy.
Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).
Disqualifiers
Patients who have received pelvic radiotherapy.
Severe renal impairment
Previous open or laparoscopic pelvic surgery.
Presence of distant metastases at diagnosis.
Trial design
Treatments tested in this trial
- Multiparametric Magnetic Resonance Imaging (mpMRI)